Literature DB >> 31820566

Bortezomib-based four-drug induction does induce a response in advanced relapsed ALL but cure remains elusive.

Yoav H Messinger1, Bruce C Bostrom1.   

Abstract

Entities:  

Keywords:  acute lymphoblastic leukemia; bortezomib; chemotherapy; children; refractory; relapse

Mesh：

Substances：

Year:  2019        PMID： 31820566     DOI： 10.1002/pbc.28115

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  3 in total

1.  Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy.

Authors:  Kai Wang; Yu Zhao; Xuan Wang; Bin Wang; Maoquan Qin; Guanghua Zhu; Huantong Wu; Zhongfeng Liu; Xueling Zheng; Huyong Zheng; Zhiguo Chen
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

2.  Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.

Authors:  Laurence C Cheung; Rebecca de Kraa; Joyce Oommen; Grace-Alyssa Chua; Sajla Singh; Anastasia M Hughes; Emanuela Ferrari; Jette Ford; Sung K Chiu; Ronald W Stam; Ursula R Kees; Sébastien Malinge; Rishi S Kotecha
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

Review 3.  Therapeutic Targeting of the Leukaemia Microenvironment.

Authors:  Vincent Kuek; Anastasia M Hughes; Rishi S Kotecha; Laurence C Cheung
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.